Pharmos Corporation

Pharmos Corporation

Pharmos Corporation was founded in 1990 and is headquartered in Iselin, New Jersey. Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutic drugs to treat a range of diseases of the nervous system in the United States and Israel. It focuses on the diseases of the nervous system, such as the disorders of the brain-gut axis, pain/inflammation, and autoimmune disorders. Pharmos's lead product candidate includes dextofisopam, a non-serotonergic agent, which is in Phase IIb clinical trials for the treatment of irritable bowel syndrome (IBS). Its product pipeline also includes VPI-013 that completed Phase IIa testing for the treatment of female sexual dysfunction and neuropathic pain; CB2-selective cannabinoids for the treatment of inflammatory/autoimmune diseases; and Tianeptine, which is in Phase I clinical trials for the treatment of IBS and functional dyspepsia. In addition, Pharmos Corporation's products under development comprise Cannabinor that has completed two Phase IIa proof of principle trials for treating pain; and NanoEmulsion drug delivery system, which is in Phase IIa clinical trial for the treatment of knee osteoarthritis. Pharmos's therapeutic drugs are also used to treat autoimmune disorders.

Contact Details

Office Address

Pharmos Corporation
99 Wood Avenue South, Suite 311
Iselin, NJ, USA 08830
Phone: (732) 452-9556
Fax: (732) 452-9557

Executives

Exec. Chairman and Principal Exec. Officer

Mr. Robert F. Johnston

Chief Financial Officer

Mr. S. Colin Neill

Business Reviews for Pharmos Corporation

Related Companies